Laboratorio de Neurofarmacología, Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón s/n, Casco de Santo Tomás, Ciudad de México C.P. 11340, Mexico.
Laboratorio de Medicina de la Conservación, Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón s/n, Casco de Santo Tomás, Ciudad de México C.P. 11340, Mexico.
Int J Mol Sci. 2023 Nov 16;24(22):16392. doi: 10.3390/ijms242216392.
The spike (S) protein of SARS-CoV-2 is a molecular target of great interest for developing drug therapies against COVID-19 because S is responsible for the interaction of the virus with the host cell receptor. Currently, there is no outpatient safety treatment for COVID-19 disease. Furthermore, we consider it of worthy importance to evaluate experimentally the possible interaction of drugs (approved by the Food and Drug Administration) and the S, considering some previously in silico and clinical use. Then, the objective of this study was to demonstrate the in vitro interaction of ivermectin with S. The equilibrium dialysis technique with UV-Vis was performed to obtain the affinity and dissociation constants. In addition, the Drug Affinity Responsive Target Stability (DARTS) technique was used to demonstrate the in vitro interaction of S with ivermectin. The results indicate the interaction between ivermectin and the S with an association and dissociation constant of Ka = 1.22 µM and Kd = 0.81 µM, respectively. The interaction was demonstrated in ratios of 1:50 pmol and 1:100 pmol (S: ivermectin) by the DARTS technique. The results obtained with these two different techniques demonstrate an interaction between S and ivermectin previously explored in silico, suggesting its clinical uses to stop the viral spread among susceptible human hosts.
SARS-CoV-2 的刺突(S)蛋白是开发针对 COVID-19 的药物疗法的重要分子靶标,因为 S 负责病毒与宿主细胞受体的相互作用。目前,COVID-19 疾病没有门诊安全治疗方法。此外,我们认为评估药物(经食品和药物管理局批准)与 S 的可能相互作用具有重要意义,考虑到一些先前的计算机模拟和临床使用。因此,本研究的目的是证明伊维菌素与 S 的体外相互作用。采用平衡透析技术结合紫外可见分光光度法获得亲和力和解离常数。此外,还使用药物亲和力响应靶稳定性(DARTS)技术来证明 S 与伊维菌素的体外相互作用。结果表明伊维菌素与 S 之间存在相互作用,其缔合和离解常数分别为 Ka = 1.22 µM 和 Kd = 0.81 µM。通过 DARTS 技术,在 1:50 pmol 和 1:100 pmol(S:伊维菌素)的比例下证明了这种相互作用。这两种不同技术的结果表明 S 与伊维菌素之间存在先前在计算机模拟中探索过的相互作用,表明其在临床上可用于阻止病毒在易感人类宿主中的传播。